Your Health, We Care
Release date: 2026-01-09 16:41:49 Recommended: 202
Capmatinib is indicated for the treatment of a specific type of non-small cell lung cancer (NSCLC). It helps inhibit the growth and proliferation of certain cancer cells.
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mesenchymal-epithelial transition (MET) exon 14 skipping mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved companion diagnostic test. The FDA has designated capmatinib as an orphan drug for this indication. Information about FDA-approved companion diagnostic tests for the detection of MET mutations in NSCLC is available on the FDA website. Current approval of this indication is based on objective response rate (ORR) and duration of response (DoR); continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
A relatively small subset of NSCLC patients (approximately 2–4%) have MET exon 14 skipping mutation-positive disease, which predicts potential responsiveness to MET inhibitor therapy. Patients with this type of lung cancer are typically female, older in age, often have adenocarcinoma histology, and carry a poor prognosis.
The efficacy and safety of capmatinib in patients with metastatic NSCLC harboring MET exon 14 skipping mutations were demonstrated in a non-randomized, multi-cohort, multinational, open-label Phase 2 study (GEOMETRY mono-1). This study enrolled adult patients with NSCLC who had MET dysregulation (i.e., MET exon 14 skipping mutation-positive or MET amplification), wild-type epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)-negative status, locally advanced or metastatic disease (Stage IIIB or IV), and at least one measurable lesion.
There are currently no known interactions between capmatinib and food or beverages.
It is unknown whether alcohol consumption affects capmatinib. However, heavy alcohol intake can slow down the immune response, making it harder for the body to fight cancer. In addition, the risk of fatigue may increase if alcohol is consumed during capmatinib treatment.
Be sure to inform your doctor about any prescription drugs, over-the-counter medications, vitamins/minerals, herbal products, and other supplements you are taking.
Specifically, before taking capmatinib, make sure to discuss with your doctor if you are using any of the following medications:
1. Itraconazole (Sporanox, Tolsura), a medication used to treat fungal infections.
2. Rifampicin (Rifadin), a medication commonly used to treat tuberculosis infections.
3. Digoxin (Lanoxin), a medication used to treat cardiac arrhythmias and certain types of heart failure.
4. Rosuvastatin (Crestor), a medication used to lower cholesterol levels.
5. Many other medications may alter the blood concentration of capmatinib, and vice versa. Please inform your doctor of all medications you are taking or have recently taken.
This may not be a complete list of medications that interact with capmatinib. Be sure to consult your doctor.
